title: Propranolol as a novel treatment for congenital visceral haemangioma.
abstract: Haemangiomas are the most common soft tissue tumours in infancy, occurring in approximately 5-10% of 1-year-old children. Current drug-based therapeutic options for large haemangiomas include corticosteroids, α-interferon and vincristin, all of which can result in harmful side effects. Recently, promising results have been reported using the non-cardio-selective β-blocker propranolol for the treatment of cutaneous capillary haemangiomas, in which a spectacular size reduction was observed during the first 7 days of treatment. We here report a similar significant and rapid inhibitory effect of propranolol on the growth of a viscerally located congenital haemangioma.
authors.affiliation: Neonatal Intensive Care Unit, AZ-St-Jan Bruges-Ostend AV, Bruges, Belgium.
authors.forename: Arnaud
authors.initials: A
authors.lastname: Vanlander
authors.forename: Wim
authors.initials: W
authors.lastname: Decaluwe
authors.forename: Michel
authors.initials: M
authors.lastname: Vandelanotte
authors.forename: Christel
authors.initials: C
authors.lastname: Van Geet
authors.forename: Luc
authors.initials: L
authors.lastname: Cornette
mesh_terms: D000008:Abdominal Neoplasms / Q000151:congenital* / Q000188:drug therapy* / Q000473:pathology; D006391:Hemangioma / Q000151:congenital* / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D011433:Propranolol / Q000627:therapeutic use*; D014470:Umbilical Cord / Q000187:drug effects / Q000473:pathology; D054079:Vascular Malformations / Q000188:drug therapy / Q000473:pathology; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D014665:Vasodilator Agents; D011433:Propranolol